5Morioka T,Emoto M,Tabata T,et al.Glycemic control is a predictor of survival for diabetic on he modialysis[J].Diabetes Care,2001,24(5):909-913.
6佐中孜,秋叶隆.透析疗法[M].北京:军事医学科学出版社,1999:171-172.
7Biesenbach G,Debska-slizien A,Zazgornik J.Nutritional status in type2 diabetic patients reuiring hemodialysis[J].Nephrol Dial Trans Plant,1999,14 (3):655-658.
8Coil L,Bonomini M,La Manna G,et al.Clinical use of profiled hemodialysis.Artif Organs,1998,22:721.
2Baigent C, Landray M J, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study Of heart and renal protection): a randomised placebo-controlled trial [J]. Lancet, 2011,377(9784): 2181-2192.
3Rossignol P, Cleland J G F, Bhandari S, et al. Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study [J]. Circulation, 2012, 125(2): 271-279.
4Zarmad F, McMurray J J, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms [J]. NewEnglJMed, 2011, 364(1): 11-21.
5Mehrotra R, Chiu Y W, Kalantar-Zadeh K, et al. Similar outcomes with hemodialysis and peritoneal dialysis in patients with end-stage renal disease [J]. Arch Internal Med, 2011, 171(2): 110-118.
6Sens F, Schott-Pethelaz A M, Labeeuw M, et al. Survival advantage of hemodialysis relative to peritoneal dialysis in patients with end-stage renal disease and congestive heart failure [J]. Kidney lnt, 2011, 80(9): 970-977.
